Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

Table 1 Baseline patient demographics (treated set)

	Total (n = 206)
Sex, n (%)
Male	97 (47.1)
Female	109 (52.9)
Median (range) age, years	44 (19–69)
Age group, n (%)
<40 years	73 (35.4)
40–50 years	66 (32.0)
51–65 years	60 (29.1)
>65 years	7 (3.4)
Race, n (%)
Caucasian	191 (92.7)
Black/African-American	15 (7.3)
Smoking history, n (%)
Never smoked	144 (69.9)
Ex-smoker^a	62 (30.1)
Mean FEV₁, L (standard deviation)
Pre-bronchodilator^b	2.433 (0.619)
Post-bronchodilator^c	2.966 (0.791)

^aCigarette smoking history of <10 pack-years and smoking cessation ≥1 year prior to enrolment
^b10 min before administration of 400 μg salbutamol
^c10–15 min after administration of 400 μg salbutamol, n = 205
FEV ₁ forced expiratory volume in 1 s

ISSN: 1465-993X